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ABSTRACT: We evaluated the effectiveness of different sizes of bioactive glass S53P4 against Staphylococcus aureus biofilms grown on
metal discs in vitro. S. aureus biofilms were cultivated on titanium discs. BAG-S53P4 (0.5–0.8mm and <45mm) were placed in contact
with the discs containing biofilms. Glass beads (0.5mm) were used as a control. After each interval, the pH from each sample was
measured. Colony forming units were counted for the biofilm recovery verification. In parallel, we tested the activity of bioactive glass
against S. aureus planktonic cells. We found that BAG-S53P4 can suppress S. aureus biofilm formation on titanium discs in vitro. The
suppression rate of biofilm cells by BAG-S53P4 <45mm was significantly higher than by BAG-S53P4 0.5–0.8mm. BAG-S53P4 has a
clear growth-inhibitory effect on S. aureus biofilms. BAG-S53P4 <45mm is more efficient against biofilm growth in vitro comparing
with BAG-S53P4 0.5–0.8mm. Bioactive glass S53P4 has potential to be used as bone substitute for the resolution of infection
complications in joint replacement surgeries and treatment of chronic osteomyelitis.  2013 Orthopaedic Research Society. Published
by Wiley Periodicals, Inc. J Orthop Res 32:175–177, 2014.
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The treatments of post-traumatic and implant-related
skeletal complications are challenging. Bone grafting
is usually required to stimulate bone healing. Several
methods of reconstructing bone defects are available
using autograft, allograft, demineralized bone matrix,
hydroxyapatite, calcium phosphate, autologous bone
marrow aspirates, bone morphogenetic proteins, and
other related growth factors.1 In treatment of bone
infections, adequate debridement is mandatory. Unfor-
tunately, this treatment often results in a poorly
vascularized large bone defect.2 Many methods have
been used to treat infected bone defects, including free
vascularized bone grafts, local muscle flaps, and
antibiotic-impregnated polymers3,4 and bone grafts.5
The bacterial colonization of host tissue or
implanted materials is promoted by the ability of the
bacteria to produce protein-specific adhesions on their
surfaces, which is followed by interactions with host
protein components, such as fibrinogen, fibronectin,
and collagen. Bacteria in biofilms evade host defenses
and are more resistant to antibiotics.6 Staphylococci
and Gram-negative bacilli are the pathogens most
commonly involved in these cases.
Bioactive glass S53P4 (BAG-S53P4; 53% silicon
dioxide, 23% sodium oxide, 20% calcium oxide, and 4%
phosphorus pentoxide) is a biocompatible, osteoconduc-
tive bone substitute, with bone bonding capacity and
antibacterial properties.3,7,8 BAG-S53P4 does not favor
adhesion or colonization of several pathogens on its
surface.9,10 Also, promising results were obtained in
dead space management in chronic osteomyeli-
tis.3,9,11,12 The ability of BAG-S53P4 to inhibit bacteri-
al growth is based on simultaneous processes that
occur when the bioactive glass reacts with body fluids.
First, sodium is released from the surface of the glass,
inducing elevation of the pH that is unfavorable for
bacteria. Further, the ions (sodium, calcium, phospho-
rus, and silicium) released from the surface increase
the osmotic pressure, creating an environment where
the bacteria cannot grow.7,8
No studies, however, show the effect of BAG-S53P4
against bacterial biofilms. The aim of this study was to
evaluate the effectiveness of two different dimensions
of BAG-S53P4 against Staphylococcus aureus biofilms
grown on metal discs in vitro.
METHODS
Bioactive Glass
Bone substitute made by bioactive glass (BAG-S53P4) as
granules sizing 0.5–0.8mm and <45mm (BonAlive Biomate-
rials Ltd., Turku, Finland) were used.
Bacterial Strains
American Type Culture Collection S. aureus (ATCC 29213)
was used. For the preparation of the inoculums, the lyophi-
lized strains were freshly grown overnight on Mu¨ller-Hinton
(MH) agar plates (Sigma–Aldrich, Hamburg, Germany).
Discrete colonies were obtained from MH agar plates and
resuspended in MH broth to a McFarland turbidity of 0.5.
Substrate for Biofilm Formation
Discs with an area of 157mm2 and made from TMZF1 alloy
(TiMo12Zr6Fe2), usually employed for joint replacement
implants confection, were purchased from Stryker GmbH &
Co KG (Duisburg, Germany).13
Activity of BAG-S53P4 Against S. aureus Biofilm
Discs were washed, autoclaved, and immersed in 48-well
plates containing 1ml of a 2 105S. aureus/ml stock solu-
tion. The plates containing the discs were incubated at 37˚C
for 24h on a rocking table (12 cycles/min) for the attachment
of planktonic cells on the disc surfaces and biofilm formation.
After 24h, the discs containing biofilms were washed three
times with distilled water to remove the planktonic cells and
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transferred to a new 48-well plate. The following samples
were placed in wells in contact with the discs: 500mg of
BAG-S53P4 (0.5–0.8mm), 500mg of BAG-S53P4 (<45mm),
and 500mg of glass beads (0.5mm) used as control. Five
hundred microliters of fresh MH bullion was added in each
well. The plates were incubated at 37˚C for 24 and 48h and 4
and 5 days. After each interval, the pH from each well was
measured, and the discs were removed, washed three times
in PBS and transferred to a 15ml Falcon tube containing
2ml of MHB. The tubes were sonicated for 1min at 100%
intensity for the disruption of the biofilms. After sonication,
20ml of the sonication fluid were added to a MH agar
plate and incubated at 37˚C for 24h. After 24h, the colony
forming units (CFUs) were manually counted for the biofilm
recovery verification. All experiments were carried out in
triplicate.
In parallel, we tested the activity of bioactive glass
against S. aureus as planktonic cells. For that we added
500mg of BAG-S53P4 (0.5–0.8mm), 500mg of BAG-S53P4
(<45mm), and 500mg of glass beads (0.5mm) in tubes
containing 2ml of a 2 105S. aureus/ml stock solution and
incubated at 37˚C for 24h. After 24h, 20ml of the incubated
fluid was added to a MH agar plate and incubated at 37˚C
for 24h. After 24h, the CFUs were counted. The experiments
were carried out in duplicate.
Statistical Analysis
The difference in the biofilm recovery after treatment with
bioactive glass between time steps was analyzed with
Freedman tests. The difference among all samples was
calculated using ANOVA and Games-Howell as post hoc
tests. Statistical analyses were carried out using SPSS 20
(IBM, Armonk, NY). Prism 5 for Windows (GraphPad
Software, Inc., La Jolla, CA) was used to create the graphs.
RESULTS
Activity of BAG-S53P4 Against S. aureus Biofilm
The discs treated with BAG-S53P4 (0.5–0.8mm) and
BAG-S53P4 (<45mm) had less CFU in comparison with
the control samples. A significant difference was observed
between the time steps and also between the substrates
(p<0.0001) where after 24h a mean of 6 CFU log10 (was
counted for the BAG-S53P4 (0.5–0.8mm) plates, a mean
of 2 CFU log10 from BAG-S53P4 (<45mm), and a mean
of 8 CFU log10 for control group (Fig. 1).
The BAG-S53P4 (0.5–0.8mm) started with a pH of
8, which increased to 11 by 5 days. The BAG-S53P4
(<45mm) showed a pH of around 10 and 11 from time
0, while the glass beads kept the pH at 8 during all
intervals (Fig. 2).
The activity of bioactive glass against S. aureus
planktonic cells showed 8 CFU log10 for BAG-S53P4 (0.5–
0.8mm) and 8 CFU log10 for glass beads, while the CFU
counting for BAG-S53P4 (<45mm) was near 0 (Fig. 3).
DISCUSSION
We examined the anti-biofilm properties of BAG-
S53P4 <45mm and BAG-S53P4 0.5–0.8mm. Smaller
granules size is recommended for smaller bone defects
and bigger granules for larger bone defects. As small
and larger bone defects can be infected with biofilm
formation, we chose to investigate both granules sizes.
A clinically important bacterial species was cultivat-
ed in broth on metal discs together with two different
BAGs. We showed that BAG-S53P4 can suppress S.
aureus biofilm formation on titanium alloy discs in
vitro. However, the dimensions of the bioactive glass
granules are an important factor for the effectiveness
of this bone substitute against biofilm growth. The
suppression rate of biofilm cells by BAG-S53P4 <45mm
was significantly higher than by BAG-S53P4 0.5–
0.8mm. These results also correlate with tests made
with BAG-S53P4 <45mm and BAG-S53P4 0.5–0.8mm
in contact with S. aureus planktonic cells, where just a
few CFU could be counted from the samples treated by
BAG-S53P4 <45mm. Our results correlate with other
studies carried out with BAGs.3,9,10
The exact mechanisms of the antibacterial action of
BAGs are unknown. High pH and osmotic effects caused
by the nonphysiological concentration of ions dissolved
from the glass have been suggested.10 We suggest that
the better activity of smaller granules can be related to
the increased surface area. Increasing surface area
increases the contact of the bioactive glass with the
aqueous environment that increases the release of ions
from BAG, raising the local pH and osmotic pressure.8,14
High pH is unfavorable to bacterial growth.3,9 Another
factor may be the high concentrations of calcium and
alkalis likely to be released from BAG that could cause
perturbations of the membrane potential of bacteria.9
Our results agree with Zhang et al.15 who affirmed that
the largest particles did not markedly prevent diffusion
between the ions inside the particle bed and simulated
Figure 1. Biofilm recovery on titanium alloy surfaces after
treatment with BAG 0.5–0.8mm, BAG <45mm, and glass beads
as control. Threshold¼8 log10.
Figure 2. pH of the wells containing biofilm grown on the
metallic surfaces and treated with BAG 0.5–0.8mm, BAG
<45mm, and glass beads as control after 0, 24, and 48h and for 4
and 5 days.
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body fluid. The higher pH values obtained with the
smaller particles depended on their large surface area.
The bigger the particles, the smaller the differences
between the pH values.15
The stability of the calcium phosphate precipitation
increased with pH. According to Lu and Leng,16 the
nucleation rate of calcium phosphate precipitation in
simulated body fluid was significantly affected by pH,
resulting in a different crystallized structure of the
precipitate. A high pH environment was favorable for
hydroxyapatite nucleation, and the hydroxyapatite
nucleation rate approached that of octacalcium phos-
phate at pH 10.16 The bone-like layer formed on the
surface of BAG-S53P4 once in contact with corporal
fluids is responsible for the osteointegration of the
material, improving the bone remodeling and there-
fore, the resistance of the tissue against infections.
The possibility of bacterial colonization is a remark-
able problem in the use of prostheses and other
medical devices BAGs have bactericidal properties on
both aerobic and anaerobic bacteria.3,10,17 Promising
results with BAG-S53P4 used in dead space manage-
ment in chronic osteomyelitis has been shown.3,12
Modifications of the surfaces of devices, for example,
by coating them with a suitable BAG, or use of BAGs
as bone substitute in joint replacement revisions may
prevent bacterial adhesion and thus prevent the
tissues around them from becoming infected.9,17
In conclusion, BAG S53P4 has a clear growth-
inhibitory effect on S. aureus biofilms. BAG-S53P4
<45mm is more efficient against biofilm growth in
vitro comparing with BAG-S53P4 0.5–0.8mm. Bioac-
tive glass S53P4 has potential to be used as bone
substitute in joint replacement surgeries aiming pre-
vention and treatment of periprosthetic infections.
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Figure 3. Quantification of planktonic cells after treatment
with BAG 0.5–0.8mm, BAG <45mm, and glass beads as control
after intervals of 0, 24, and 48h and of 4 and 5 days.
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